Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$23.49 USD
+0.32 (1.38%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $23.47 -0.02 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.49 USD
+0.32 (1.38%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $23.47 -0.02 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Zacks News
Medtronic's (MDT) EV ICD Pilot Study Results Encourage
by Zacks Equity Research
The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.
Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fall year over year in Q1.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) has been gaining investor confidence on robust performance.
National Vision's (EYE) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.
BioScrip's Option Care Merger on Track, Q1 Loss Narrows
by Zacks Equity Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.
Wright Medical (WMGI) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.
OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates
by Zacks Equity Research
Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.
Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.
Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall
by Zacks Equity Research
Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.
McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.
Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.
Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.
Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered
by Zacks Equity Research
Inogen (INGN) slashes revenue and net income guidance for 2019.
DaVita (DVA) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DaVita (DVA) gains from international revenues in Q1.
Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.
Dentsply International (XRAY) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 28.95% and 3.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.